Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
2.220
+0.030 (1.37%)
At close: May 9, 2025, 4:00 PM
2.220
0.00 (0.00%)
After-hours: May 9, 2025, 7:00 PM EDT

Alto Neuroscience Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-61.43-36.31-27.71-9.19
Depreciation & Amortization
0.50.370.340.15
Loss (Gain) From Sale of Assets
0.050.14--
Asset Writedown & Restructuring Costs
0.74---
Stock-Based Compensation
7.632.891.760.23
Other Operating Activities
1.030.150.630.13
Change in Accounts Receivable
--1.16-1.29
Change in Accounts Payable
0.52-0.631.010.46
Change in Other Net Operating Assets
3.54-0.072.420.26
Operating Cash Flow
-47.42-33.45-20.39-9.26
Capital Expenditures
-2.08-0.47-0.73-0.68
Investing Cash Flow
-2.08-0.47-0.73-0.68
Long-Term Debt Issued
1.25-9.83-
Net Debt Issued (Repaid)
1.25-9.83-
Issuance of Common Stock
137.770.180.040.01
Other Financing Activities
-3.33-2.05-0.34-0.21
Financing Cash Flow
135.6968.1343.7931.69
Foreign Exchange Rate Adjustments
-0.01-0.01-0.02-0.05
Net Cash Flow
86.1834.222.6421.7
Free Cash Flow
-49.5-33.92-21.13-9.94
Free Cash Flow Margin
----4734.29%
Free Cash Flow Per Share
-2.01-9.09-6.13-4.12
Cash Interest Paid
10.91--
Levered Free Cash Flow
-32.29-23.45-12.3-
Unlevered Free Cash Flow
-31.44-22.6-12.3-
Change in Net Working Capital
-5.391.76-4.57-
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q